scispace - formally typeset
J

Jamie Case

Researcher at Scripps Health

Publications -  73
Citations -  2864

Jamie Case is an academic researcher from Scripps Health. The author has contributed to research in topics: Progenitor cell & CD34. The author has an hindex of 22, co-authored 72 publications receiving 2703 citations. Previous affiliations of Jamie Case include Indiana University – Purdue University Indianapolis & Boston Children's Hospital.

Papers
More filters
Book ChapterDOI

Children with Solid Tumors: Identification of Hematopoietic and Endothelial Progenitor Cells as Biomarkers

TL;DR: In this chapter, data from pediatric solid tumor studies will be analyzed and reviewed to determine which current biomarkers have the most potential for influencing treatment and/or outcome.
Journal ArticleDOI

The Advantage of Multiple Listing Continues in the Kidney Allocation System Era.

TL;DR: In this paper, the authors evaluated the association between multilisting status and access to a deceased donor kidney transplant (DDKT) to determine if ML provides a longterm advantage regarding wait-list mortality and recipient outcomes.

Research Report Prior Cryopreservation of Ex Vivo-Expanded Cord Blood Cells Is Not Detrimental to Engraftment as Measured in the NOD-SCID Mouse Model

TL;DR: Results suggest that prior cryopreservation does not prevent expanded cells engrafting in NODSCID mice and suggest that SCID Engrafting Potential (SEP) is higher than freshly expanded CD34 1 cells.
Journal ArticleDOI

Mitigation of radiation exposure during surgical hepatectomy after yttrium-90 radioembolization.

TL;DR: In this paper, the level of radiation exposure to the transplant surgeon when explanting an irradiated liver before the recommended decay period was determined, based on the explanted liver of a patient who received Y-90 therapy 46 h prior to orthotopic liver transplant.
Journal ArticleDOI

UNOS/OPTN Data-guided Assessment of Focal Segmental Glomerulosclerosis After Kidney Transplantation and Evaluation of Immunosuppressive Protocols in a Steroid-free Center.

TL;DR: In this paper, the impact of a rapid low-dose steroid withdrawal immunosuppression (IS) protocol on FSGS disease recurrence over a 10-y period was evaluated.